PMID- 36925683
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230318
IS  - 2380-6761 (Print)
IS  - 2380-6761 (Electronic)
IS  - 2380-6761 (Linking)
VI  - 8
IP  - 2
DP  - 2023 Mar
TI  - Magnetic nanoparticles enhance the cellular immune response of dendritic cell 
      tumor vaccines by realizing the cytoplasmic delivery of tumor antigens.
PG  - e10400
LID - 10.1002/btm2.10400 [doi]
LID - e10400
AB  - Dendritic cells (DCs)-based tumor vaccines have the advantages of high safety and 
      rapid activation of T cells, and have been approved for clinical tumor treatment. 
      However, the conventional DC vaccines have some severe problems, such as poor 
      activation of DCs in vitro, low level of antigen presentation, reduced cell 
      viability, and difficulty in targeting lymph nodes in vivo, resulting in poor 
      clinical therapeutic effects. In this research, magnetic nanoparticles 
      Fe(3)O(4)@Ca/MnCO(3) were prepared and used to actively and efficiently deliver 
      antigens to the cytoplasm of DCs, promote antigen cross-presentation and DC 
      activation, and finally enhance the cellular immune response of DC vaccines. The 
      results show that the magnetic nanoparticles can actively and quickly deliver 
      antigens to the cytoplasm of DCs by regulating the magnetic field, and achieve 
      cross-presentation of antigens. At the same time, the nanoparticles degradation 
      product Mn(2+) enhanced immune stimulation through the interferon gene 
      stimulating protein (STING) pathway, and another degradation product Ca(2+) 
      ultimately promoted cellular immune response by increasing autophagy. The DC 
      vaccine constructed with the magnetic nanoparticles can more effectively migrate 
      to the lymph nodes, promote the proliferation of CD8(+) T cells, prolong the time 
      of immune memory, and produce higher antibody levels. Compared with traditional 
      DC vaccines, cytoplasmic antigen delivery with the magnetic nanoparticles 
      provides a new idea for the construction of novel DC vaccines.
CI  - (c) 2022 The Authors. Bioengineering & Translational Medicine published by Wiley 
      Periodicals LLC on behalf of American Institute of Chemical Engineers.
FAU - Huang, Linghong
AU  - Huang L
AUID- ORCID: 0000-0002-8106-6815
AD  - Department of Biomedical Engineering Jinan University Guangzhou China.
FAU - Liu, Zonghua
AU  - Liu Z
AD  - Department of Biomedical Engineering Jinan University Guangzhou China.
FAU - Wu, Chongjie
AU  - Wu C
AD  - Department of Bone and Joint Surgery The First Affiliated Hospital of Jinan 
      University, Jinan University Guangzhou China.
FAU - Lin, Jiansheng
AU  - Lin J
AD  - Department of Anatomy Hunan University of Chinese Medicine Changsha China.
FAU - Liu, Ning
AU  - Liu N
AD  - Department of Bone and Joint Surgery The First Affiliated Hospital of Jinan 
      University, Jinan University Guangzhou China.
LA  - eng
PT  - Journal Article
DEP - 20220909
PL  - United States
TA  - Bioeng Transl Med
JT  - Bioengineering & translational medicine
JID - 101689146
PMC - PMC10013825
OTO - NOTNLM
OT  - DC vaccines
OT  - antigen delivery
OT  - magnetic nanoparticles
COIS- The authors declare that they have no competing financial interests or personal 
      relationships that could have appeared to influence the work reported in this 
      paper.
EDAT- 2023/03/18 06:00
MHDA- 2023/03/18 06:01
PMCR- 2022/09/09
CRDT- 2023/03/17 02:37
PHST- 2022/03/21 00:00 [received]
PHST- 2022/07/02 00:00 [revised]
PHST- 2022/08/16 00:00 [accepted]
PHST- 2023/03/17 02:37 [entrez]
PHST- 2023/03/18 06:00 [pubmed]
PHST- 2023/03/18 06:01 [medline]
PHST- 2022/09/09 00:00 [pmc-release]
AID - BTM210400 [pii]
AID - 10.1002/btm2.10400 [doi]
PST - epublish
SO  - Bioeng Transl Med. 2022 Sep 9;8(2):e10400. doi: 10.1002/btm2.10400. eCollection 
      2023 Mar.